TESMIN

Across TCGA pan-cancer cohorts, TESMIN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TESMIN data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TESMIN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TESMIN expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LIHC, HNSC, and LUAD are the cancer types where TESMIN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
HNSC	OS	Median	IV	0.102	0.733	<.001	6	view →
LUAD	DFS	Median	II,III,IV	1.000	0.233	.044	2	view →
UCEC	DFS	Median	II,III,IV	0.900	0.440	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TESMIN–LIHC (OS)

Open the LIHC breakdown →